Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
61Cu-NuriPro
- Development stage
- Unknown
- Lead developer
- Nuclidium
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
61Cu-NuriPro is a copper-based diagnostic radiopharmaceutical developed for PET imaging of prostate cancer. It specifically targets the Prostate-Specific Membrane Antigen (PSMA), a biomarker highly expressed in prostate carcinoma cells, enabling precise diagnosis and disease staging. The agent uses copper-61 (with a half-life of approximately 3.3 hours) chelated to a PSMA-targeting ligand (NODAGA), allowing for delayed imaging and improved detection of small metastases compared to conventional fluorine-based tracers. Its longer half-life facilitates broader distribution and on-demand preparation at room temperature, simplifying logistics and workflow in clinical settings. The drug is currently being evaluated in Phase I clinical trials as an imaging tool for patients with PSMA-positive prostate cancer[1][2][5][6][7][8][9].
- Brand names
- NuriPro
- Other names
- Cu-61 NuriProCu61 NuriProCu 61 NuriPro⁶¹Cu-NuriPro61Cu-based NuriPro radiodiagnostic
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 61Cu-NuriPro.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 61Cu-NuriPro.